Transcriptome Signature Reversion as a Method to Reposition Drugs Against Cancer for Precision Oncology

Area of Science:

• Oncology
• Pharmacology
• Bioinformatics

Background:

• Transcriptome signature reversion (TSR) is a novel drug repurposing strategy.
• TSR hypothesizes that drugs normalizing disease-associated gene expression may treat the disease.
• This approach offers a promising avenue for identifying novel cancer therapeutics from existing non-cancer drugs.

Purpose of the Study:

• To review the methodology of Transcriptome Signature Reversion (TSR).
• To critically discuss key studies employing TSR for cancer drug discovery.
• To explore potential improvements and future applications of TSR in precision oncology.

Main Methods:

• Literature review of TSR methodology and key studies.
• Critical analysis of TSR's theoretical underpinnings and practical applications.
• Discussion of conceptual and computational advancements for TSR.

Main Results:

• TSR methodology enables the identification of potential therapeutic candidates by analyzing gene expression profiles.
• Existing studies demonstrate the feasibility of TSR in drug repositioning for various diseases, including cancer.
• The review highlights the potential of TSR to accelerate drug discovery and development.

Conclusions:

• TSR is a promising strategy for drug repositioning in oncology.
• Further methodological and computational refinements are needed to optimize TSR.
• TSR holds significant potential for future applications in precision oncology trials.